This website is up to date through May 10, 2013. There are no new drugs under consideration at this moment.

Worldwide, the Brugada syndrome has been recognized as an important cause of sudden cardiac death at a relatively young age. Brugada syndrome is diagnosed in the presence of specific electrocardiographic abnormalities (known as the type-1 Brugada syndrome ECG) combined with an absence of gross structural abnormalities and several other criteria. Further, Brugada syndrome often shows familial aggregation. The presence of this type-1 ECG in particular has been linked to an increased risk for ventricular tachyarrhythmias, cardiac arrest and sudden death in Brugada syndrome patients. Importantly, many drugs have been reported to induce the type-1 ECG and/or (fatal) arrhythmias in Brugada syndrome patients. Therefore, it is necessary to advice patients with Brugada syndrome not to use these drugs, or only in controlled conditions.

You can find lists of the drugs that are (preferably) avoided by Brugada syndrome patients below. Just click on the bar and you will be taken to the appropriate page. Also you can choose to see potential anti-arrhythmic drugs, diagnostic drugs including ECG examples and a page with summary letters in many different languages which list all the drugs that need to be (preferably) avoided. A translation tool is also provided, and you can find frequently asked questions here.

Many drugs have been associated with the type-1 ECG and/or with arrhythmias in Brugada syndrome patients. We have divided these drugs into four lists (together with the available evidence in the literature and a recommendation from the BrugadaDrugs.org Advisory Board) :

• Red list: drugs that should be avoided by Brugada syndrome patients
• Orange list: drugs that preferably should be avoided by Brugada syndrome patients
• Green list: drugs that may have an antiarrhythmic effect in Brugada syndrome patients
• Blue list: drugs used to diagnose the Brugada syndrome ECG
• The Purple list contains a complete list of the above mentioned drugs to (preferably) avoid for patients to give to all their health care providers

It should be seriously considered to advise patients with Brugada syndrome to avoid drugs from the Red list (drugs to be avoided) because these drugs might result in arrhythmias, or to use these drugs only after extensive consideration and/or in controlled conditions. Drugs from the Orange list (drugs preferably avoided) have been associated with the appearance of the Brugada syndrome ECG and are therefore considered to be potentially proarrhythmic in patients with Brugada syndrome. However, this has not been documented clearly and some patients may benefit from these drugs for other reasons. Considering alternative drugs, administration in controlled conditions or close monitoring may be suitable. Please note that although the most appropriate treatment for Brugada syndrome patients is under discussion among experts, avoidance of (potential) proarrhythmic drugs and fever (a well known trigger of cardiac events in Brugada syndrome) is generally accepted to be an important part of (prophylactic) treatment. However, some patients may be appropriately treated with an implantable cardioverter defibrillator. Furthermore, some Brugada syndrome patients seem to perform well on quinidine.

There are two consensus reports on the Brugada syndrome (Wilde et al. 2002, and Antzelevitch et al. 2005)

Please cite this site as: Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA. Drugs and Brugada syndrome patients: review of the literature, recommendations and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6(9):1335-1341. (Free available from Heart Rhythm, PubMed link here).

For Long-QT syndrome a similar website can be found at www.qtdrugs.org. This website is initiated by the Critical Path Institute, University of Arizona, to aid physicians who treat patients with Long-QT syndrome and lists drugs to be avoided by patients with Long-QT syndrome.

Notes about the lists and site:

• On this site we summarized those drugs of which there are reports in the literature on an association between these drugs and the Brugada syndrome
• We advice our Brugada syndrome patients to give this letter to all of their health care providers.
• It should be clear to the users of this site that the principal limitation of the association between certain drugs, Brugada syndrome and arrhythmias, is that there are quite often only (a number of) case reports and experimental studies suggesting an effect in Brugada syndrome. Further, there may be conflicting results and  large variability for Brugada syndrome patients in their response to certain drugs. This response may also differ in different conditions (e.g. with or without fever, drug in therapeutic range, overdosed or in combination with other drugs etc.). Clinical decision making should be based on more than the presence or absence of a (single) association in another patient.
• Drugs are listed with up to 4 common brand names. There are several brand names for many of the drugs, which are not all listed. It is always important to look at the active drugs in medicines that contain a combination of drugs.
• Lists contain links to DrugBank or PubChem and also (several) PubMed links to articles on the association between the drug and Brugada syndrome.
• The BrugadaDrugs.org Advisory Board provides consultation and aids in making decisions regarding these drug lists.
• This site has been developed in close analogy to www.qtdrugs.org, a website initiated by the Critical Path Institute, University of Arizona, to aid physicians who treat patients with Long QT syndrome.

Please also read our Disclaimer.